Table 2.
Laboratory findings and PFT results between the PPF-ASS and non-PPF-ASS groups
| Total (n = 72) | PPF-ASS (n = 18) | Non-PPF-ASS (n = 54) | χ2/t | p | |
|---|---|---|---|---|---|
| NLR | 4.5 ± 3.5 | 6.8 ± 5.1 | 3.8 ± 2.4 | N/A | 0.001* |
| LMR | 3.1 ± 1.8 | 3.1 ± 2.1 | 3.1 ± 1.7 | N/A | 0.594 |
| PaO2/FiO2 ratio | 310.5 ± 84.5 | 275.4 ± 83.6 | 322.2 ± 82.2 | 0.104 | 0.041* |
| LDH, U/L | 597.2 ± 501.8 | 886.3 ± 736.8 | 500.8 ± 354.1 | N/A | 0.020* |
| CRP, mg/L | 19.9 ± 41.8 | 39.6 ± 65.7 | 13.8 ± 28.0 | N/A | 0.059 |
| ESR, mm/h | 21.8 ± 23.7 | 29.2 ± 33.3 | 19.3 ± 19.3 | N/A | 0.298 |
| ALT, U/L | 39.8 ± 34.3 | 50.5 ± 36.5 | 36.2 ± 33.2 | N/A | 0.057 |
| AST, U/L | 31.3 ± 23.7 | 37.9 ± 24.7 | 29.1 ± 23.3 | N/A | 0.170 |
| Creatine kinase, UI/L | 414.9 ± 890.6 | 805.8 ± 1530.6 | 284.6 ± 491.8 | N/A | 0.224 |
| PFT results at diagnosis, % predicted | |||||
| FVC | 69.1 ± 12.8 | 65.2 ± 11.1 | 70.4 ± 13.2 | − 1.498 | 0.139 |
| DLCO | 60.0 ± 14.7 | 53.8 ± 15.9 | 62.1 ± 13.8 | − 2.126 | 0.037* |
Data are presented as the mean ± standard deviation or n (%)
ASS anti-synthetase syndrome, ALT alanine aminotransferase, AST aspartate aminotransferase, CRP C-reactive protein, DLCO diffusing capacity for carbon monoxide, FVC forced vital capacity, ESR erythrocyte sedimentation rate, LDH lactate dehydrogenase, LMR lymphocyte-to-monocyte ratio, N/A not applicable, NLR neutrophil-to-lymphocyte ratio, PFT pulmonary function test, PPF progressive pulmonary fibrosis
*p < 0.05